Asset Details
Do you wish to reserve the book?
Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
Do you wish to request the book?
Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes
2025
Overview
Aims/Introduction This study aimed to evaluate and compare the effectiveness of oral semaglutide after adding to or switching from incretin‐related drugs by assessing the changes in HbA1c and body weight (BW) in participants with type 2 diabetes in clinical settings. Materials and Methods A total of 368 participants were divided into groups according to antidiabetic medications before oral semaglutide treatment; incretin‐related drug‐naïve (naïve), switching from dipeptidyl peptide‐4 inhibitors (DPP‐4i) or glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) groups. Adjusted mean changes in HbA1c and BW at 6 months after oral semaglutide administration were compared among the three groups. Similar analyses were performed in the GLP‐1 RAs group between GLP‐1RAs before switching. Results Mean change of HbA1c in DPP‐4i and GLP‐1 RA groups was −0.67% (95% confidence interval [CI]: −0.79 to −0.54) and −0.13% (95% CI: −0.40 to 0.15), respectively, which were significantly smaller than incretin‐related drug‐naïve group; −0.85% (95% CI: −1.08 to −0.62). Mean change in BW between the naïve and DPP‐4i groups had no differences; however, these changes were lower in the GLP‐1 RA group than in the naïve group. Mean change in HbA1c between pretreatment with GLP‐1 RAs had no differences; however, the mean change in BW in the dulaglutide group was significantly higher than that in the injectable semaglutide group. Conclusion Oral semaglutide reduced HbA1c levels and BW after adding or switching from other incretin‐related drugs in Japanese participants with type 2 diabetes. Oral semaglutide reduced HbA1c levels and BW after adding or switching from other incretin‐related drugs in Japanese participants with type 2 diabetes. Oral semaglutide had effects on HbA1c and BW similar to that of injectable GLP‐1 RAs.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Aged
/ Diabetes
/ Diabetes mellitus (non-insulin dependent)
/ Diabetes Mellitus, Type 2 - drug therapy
/ Dipeptidyl peptidase‐4 inhibitor
/ Dipeptidyl-Peptidase IV Inhibitors - administration & dosage
/ Dipeptidyl-Peptidase IV Inhibitors - therapeutic use
/ Female
/ Glucagon
/ Glucagon-Like Peptide-1 Receptor Agonists
/ Glucagon-Like Peptides - administration & dosage
/ Glucagon-Like Peptides - analogs & derivatives
/ Glucagon-Like Peptides - therapeutic use
/ Glucose
/ Glycated Hemoglobin - analysis
/ Humans
/ Hypoglycemic Agents - administration & dosage
/ Hypoglycemic Agents - therapeutic use
/ Incretins - administration & dosage
/ Insulin
/ Male
/ Original
/ Peptides
